Q-omics provides the consensus-scored FABP5P3 profile across patient tissues and cancer cell-line models. FABP5P3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FABP5P3 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, FABP5P3 RNA expression shows 12,943 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, KICH, and ESCA as cancer lineages where FABP5P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FABP5P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FABP5P3 survival associations across molecular data types. FABP5P3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FABP5P3 RNA expression–survival associations across cancer types. High FABP5P3 expression shows unfavorable associations in KIRC, ACC, LGG and BRCA, but favorable associations in OV and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FABP5P3 RNA expression.
This table summarizes FABP5P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for FABP5P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FABP5P3 shows lower tumor expression in KICH, BRCA, THCA and KIRC and higher tumor expression in LIHC and HNSC. The KICH box plot shows higher FABP5P3 RNA expression in normal versus tumor tissue (log2 FC = −0.189, t-test p < 0.001).
This table shows molecular features associated with FABP5P3 in patient tissues and cancer cell lines. In patient samples, FABP5P3 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, FABP5P3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN.
